Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors

Blood

Volumn 87, Issue 1, 1996, Pages 51-58

  Anderson, Jeanne E ^a   Appelbaum, Frederick R ^b   Schoch, Gary ^b   Gooley, Ted ^b   Anasetti, Claudio ^b   Bensinger, William I ^b   Bryant, Eileen ^b   Buckner, C Dean ^b   Chauncey, Thomas R ^b   Clift, Reginald A ^b   Doney, Kristine ^b   Flowers, Mary ^b   Hansen, John A ^b   Martin, Paul J ^b   Matthews, Dana C ^b   Sanders, Jean E ^b   Shulman, Howard ^b   Sullivan, Keith M ^b   Witherspoon, Robert P ^b   Storb, Rainer ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; PHENYTOIN; TACROLIMUS;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOCRIT; HLA MATCHING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KARYOTYPING; LEUKOCYTE COUNT; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SEIZURE; SURVIVAL RATE; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT; WHOLE BODY RADIATION;

EID: 13344282097     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.1.51.51     Document Type: Article

References (33)

1. Jacobs A: Genetic lesions in preleukaemia. Leukemia 5:277, 1991
2. Ganser A, Hoelzer D: Clinical course of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:607, 1992
3. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood 74:395, 1989
4. Anderson JE, Appelbaum FR, Storb R: An update on allogeneic marrow transplantation for myelodysplastic syndrome. Leuk Lymphoma 17:95, 1995
5. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Doney K, Martin PJ, Sanders JE, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA, Storb R: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677, 1993
6. Ratanatharathorn V, Karanes C, Uberti J, Lum LG, de Planque MM, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M, Sensenbrenner LL: Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81:2194, 1993
7. Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nantel SH, Klingemann HG, Phillips GL: Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10:445, 1992
8. Sutton L, Leblond V, Le Maignan C, Jouet JP, Keuntz M, Gluckman E, Blaise D, Marit G, Attal M, Troussard X, Bordigoni P, Cahn JY, Ribaud P: Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: Outcome of 86 patients. Bone Marrow Transplant 7:39, 1991 (suppl 2)
9. DeWitte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lonnqvist B, Beelen D, Ferrant A, Gmur J, Liu Yin J, Troussard X, Cahn J, Van Lint M, Gratwohl A: Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: A survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74:151, 1990
10. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH: Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol 8.1707, 1990
11. O'Donnell MR, Nademanee AP, Snyder DS, Schimdt GM, Parker PM, Bierman PJ, Fahey JL, Stein AS, Krance RA, Stock AD, Forman SJ, Blume KG: Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 5:1822, 1987
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
13. Appelbaum FR, Barral J, Storb R, Ramberg R, Doney K, Sale GE, Thomas ED: Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 15:1134, 1987
14. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon RP, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
15. Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C, Appelbaum F, Doney K, Martin P, Sullivan K, van der Jagt R, Witherspoon R, Jusko WJ, Zager RA, Deeg HJ: Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single center study. Blood 85:3746, 1995
16. Fisher LD, Van Belle G: Biostatistics: Methodology for the Health Sciences. New York, NY, Wiley, 1993
17. Durnam DM, Anders KJR, Fisher L, O'Quigley J, Bryant EM, Thomas ED: Analysis of the origin of marrow cells in BMT recipients using a Y chromosome specific in situ hybridization assay. Blood 74:2220, 1989
18. Scharf SJ, Smith AG, Hansen JA, Mcfarland C, Erlich HA: Quantitative determiniation of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity. Blood 85:1954, 1995
19. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC: Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet 48:137, 1991
20. Tutschka PJ, Copelan EA, Kapoor N: Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation. Transplant Proc 21:2952, 1989
21. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR. Marrow transplantation for chronic myeloid leukemia. A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
22. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P, Mellander L, Jacobsen N: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 83:2723, 1994
23. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP, Milpied N, Attal M, Michallet M, Ifrah N, Kuentz M, Dauriac C, Bordigoni P, Gratecos N, Guilhot F, Guyotat D, Gouvernet J, Gluckman E: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 79:2578, 1992
24. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, Masaoka T, McGlave PB, Messner H, O'Reilly RJ, Reiffers J, Rimm AA, Speck B, Veum-Stone JA, Wingard JR, Zwaan FE, Bortin MM: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235, 1993
25. Thomas ED, Clift RA: Indications for marrow transplantation in chronic myelogenous leukemia. Blood 73:861, 1989
26. Anderson JE, Anasetti C, Appelbaum FR, Hansen JA, Storb R: Allogeneic marrow transplantation for myelodysplastic syndrome using unrelated donors. Leuk Res 18:26, 1994 (suppl)
27. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328:593, 1993
28. Mufti GJ: A guide to risk assessment in the primary myelodysplastic syndrome. Hematol Oncol Clin North Am 6:587, 1992
29. Goasguen JE, Garand R, Bizet M, Bremond JL, Gardais J, Callat MP, Accard F, Chaperon J: Prognostic factors of myelodysplastic syndromes - A simplified 3-D scoring system. Leuk Res 14:255, 1990
30. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W: Primary myelodysplastic syndromes: Analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52, 1992
31. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 7:1315, 1993
32. Clift RA, Buckner CD, Appelbaum FR, Schoch G, Petersen FB, Bensinger WE, Sanders J, Sullivan KM, Storb R, Singer J, Hansen JA, Thomas ED: Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 10:1723, 1992
33. Castro-Malaspina H, Childs B, Gillio A, Papadopoulos E, Boulad F, Young J, Small T, MacKinnon S, Kernan N, Collins N, Reyes B, O'Reilly RJ: Improved disease-free survival in patients with low risk (< 5% marrow blasts) myelodysplastic syndromes treated with HLA-identical sibling-derived T-cell depleted (SBA-E-) marrow transplants. Blood 84:518a, 1994 (abstr, suppl 1)